Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Pacritinib – is it safe for treating MF?

Ruben Mesa • 2 Jun 2017
ASCO 2017
Myelofibrosis Pacritinib

Ruben Mesa, MD, FACP, from the Mayo Cancer Clinic Center, Rochester, MN, talks to us about current advancements in studies on pacritinib, a JAK2/FLT3 inhibitor that has been proven to be superior to the best alternative therapy for myelofibrosis (MF), particularly in those with marked thrombocytopaenia, but had previously been put on hold in clinical studies due to concerns with its toxicity. He states that pacritinib has now been reinstated in clinical research and current studies are focused on determining the safest effective dose of the drug for treating MF (NCT03165734). This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

More from Ruben Mesa

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
How meaningful benefit in MPNs could evolve over the next five years
2:04
How meaningful benefit in MPNs could evolve over the next five years
Ruben Mesa • 2 Oct 2026
Insights into the evolving treatment landscape for MPNs: current state and future directions
2:22
Insights into the evolving treatment landscape for MPNs: current state and future directions
Ruben Mesa • 12 Jun 2026

Related Videos

When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026
Emerging therapeutic strategies and future directions in MPNs
3:00
Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova • 4 Oct 2026
MPN Progression Registry: insights into the work of the MPN Research Foundation
19:15
MPN Progression Registry: insights into the work of the MPN Research Foundation
David Shoultz et al. • 2 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals